RU2225220C1 - Слитый белок, обладающий in vivo повышенной активностью эритропоэтина - Google Patents
Слитый белок, обладающий in vivo повышенной активностью эритропоэтина Download PDFInfo
- Publication number
- RU2225220C1 RU2225220C1 RU2002123438/15A RU2002123438A RU2225220C1 RU 2225220 C1 RU2225220 C1 RU 2225220C1 RU 2002123438/15 A RU2002123438/15 A RU 2002123438/15A RU 2002123438 A RU2002123438 A RU 2002123438A RU 2225220 C1 RU2225220 C1 RU 2225220C1
- Authority
- RU
- Russia
- Prior art keywords
- erythropoietin
- fused protein
- carboxy
- fused
- fusion protein
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract 5
- 102000003951 Erythropoietin Human genes 0.000 title claims abstract 4
- 108090000394 Erythropoietin Proteins 0.000 title claims abstract 4
- 229940105423 erythropoietin Drugs 0.000 title claims abstract 4
- 238000001727 in vivo Methods 0.000 title claims abstract 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims abstract 4
- 102000036693 Thrombopoietin Human genes 0.000 claims abstract 4
- 108010041111 Thrombopoietin Proteins 0.000 claims abstract 4
- 102000044890 human EPO Human genes 0.000 claims abstract 4
- 150000001413 amino acids Chemical class 0.000 claims abstract 3
- 108020004707 nucleic acids Proteins 0.000 claims abstract 3
- 102000039446 nucleic acids Human genes 0.000 claims abstract 3
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 3
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Изобретение относится к слитому белку, обладающему in vivo повышенной активностью эритропоэтина. В слитом белке пептидный фрагмент карбоксильного конца тромбопоэтина аминокислоты 337-353 слит с карбоксильным концом эритропоэтина человека. Изобретение также включает нуклеиновую кислоту, кодирующую слитый белок, и способ его получения. Преимущество изобретения заключается в том, что слитый белок имеет значительно увеличенный период полужизни in vivo вследствие повышенного содержания углеводов без потери активности, присущей эритропоэтину, и не вызывает никакой антигенности в случае применения в организме человека. 3 с. и 2 з.п.ф-лы, 5 ил.
Description
Текст описания в факсимильном виде (см. графическую часть)л
Claims (5)
1. Слитый белок, обладающий in vivo повышенной активностью эритропоэтина (ЕРО) человека, в котором карбоксиконцевой пептид (СТР), содержащий, по меньшей мере, аминокислоты 337-353 тромбопоэтина (ТРО), слит с ЕРО человека по карбоксильному концу ЕРО человека.
2. Слитый белок по п.1, в котором карбоксиконцевой пептид имеет аминокислотную последовательность SEQ ID NO:2.
3. Слитый белок по п.1, в котором карбоксиконцевой пептид включает в себя аминокислоты ТРО в положениях 176-353, последовательность которых приведена в SEQ ID NO:1.
4. Нуклеиновая кислота, кодирующая слитый белок по любому из пп.1-3.
5. Способ получения слитого белка по любому из пп.1-3, предусматривающий культивирование линии клеток-хозяев, трансформированных рекомбинантным вектором, содержащим нуклеиновую кислоту по п.4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0074975A KR100467750B1 (ko) | 2001-11-29 | 2001-11-29 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| KR2001-74975 | 2001-11-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2225220C1 true RU2225220C1 (ru) | 2004-03-10 |
| RU2002123438A RU2002123438A (ru) | 2004-03-27 |
Family
ID=36821313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002123438/15A RU2225220C1 (ru) | 2001-11-29 | 2002-08-30 | Слитый белок, обладающий in vivo повышенной активностью эритропоэтина |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7098318B2 (ru) |
| EP (1) | EP1319712B1 (ru) |
| JP (1) | JP3860097B2 (ru) |
| KR (1) | KR100467750B1 (ru) |
| CN (1) | CN100390201C (ru) |
| AR (1) | AR036384A1 (ru) |
| AT (1) | ATE460483T1 (ru) |
| AU (1) | AU2002300359B2 (ru) |
| BR (1) | BRPI0203394B1 (ru) |
| CA (1) | CA2394572C (ru) |
| DE (2) | DE60235603D1 (ru) |
| ES (1) | ES2339426T3 (ru) |
| FR (1) | FR2832716B1 (ru) |
| GB (1) | GB2382580B (ru) |
| IT (1) | ITMI20021803A1 (ru) |
| MX (1) | MXPA02008131A (ru) |
| MY (1) | MY122935A (ru) |
| NZ (1) | NZ520442A (ru) |
| RU (1) | RU2225220C1 (ru) |
| SG (1) | SG117416A1 (ru) |
| TW (1) | TWI237056B (ru) |
| WO (1) | WO2003046013A1 (ru) |
| ZA (1) | ZA200206172B (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| EP1670492A4 (en) * | 2003-09-29 | 2009-07-08 | Warren Pharmaceuticals Inc | FABRIC PROTECTION CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPTICEMIA AND THE FORMATION OF ADHESIONS |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| WO2007092252A2 (en) * | 2006-02-03 | 2007-08-16 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| CA2720628A1 (en) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| CN101863982A (zh) * | 2009-04-17 | 2010-10-20 | 哈药集团生物工程有限公司 | 一种用于升高血小板的融合蛋白及其制备方法 |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| CN103864913A (zh) * | 2012-12-18 | 2014-06-18 | 联亚生技开发股份有限公司 | 重组蛋白 |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| EP3310347B1 (en) | 2015-06-19 | 2021-08-04 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| KR20240006077A (ko) | 2016-07-11 | 2024-01-12 | 옵코 바이오로직스 리미티드 | 지속성 응고 인자 vii 및 그 제조 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3045539B2 (ja) * | 1989-02-21 | 2000-05-29 | ワシントン ユニバーシティ | 改変型生殖ホルモン |
| AU5355790A (en) * | 1989-04-19 | 1990-11-16 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
| US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| IL110669A (en) * | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
| SG47030A1 (en) * | 1994-01-03 | 1998-03-20 | Genentech Inc | Thrombopoietin |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| CA2212006A1 (en) * | 1995-02-03 | 1996-08-08 | G.D. Searle & Co. | Novel c-mpl ligands |
| AU8182298A (en) * | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
| US6242570B1 (en) * | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
| ES2297889T3 (es) * | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| US6342220B1 (en) * | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO1999057147A1 (fr) * | 1998-04-30 | 1999-11-11 | Kirin Brewery Company, Limited | Mutants de la thrombopoietine humaine |
| EP1200124B1 (en) * | 1999-07-13 | 2008-09-10 | Bolder Biotechnology, Inc. | Erythropoietin-immunoglobulin fusion proteins |
| JP2003514552A (ja) * | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
-
2001
- 2001-11-29 KR KR10-2001-0074975A patent/KR100467750B1/ko not_active IP Right Cessation
-
2002
- 2002-07-24 CA CA002394572A patent/CA2394572C/en not_active Expired - Fee Related
- 2002-07-26 TW TW091116686A patent/TWI237056B/zh not_active IP Right Cessation
- 2002-07-26 WO PCT/KR2002/001420 patent/WO2003046013A1/en active Search and Examination
- 2002-07-30 MY MYPI20022857A patent/MY122935A/en unknown
- 2002-07-30 AU AU2002300359A patent/AU2002300359B2/en not_active Ceased
- 2002-07-30 NZ NZ520442A patent/NZ520442A/en not_active IP Right Cessation
- 2002-08-01 DE DE60235603T patent/DE60235603D1/de not_active Expired - Lifetime
- 2002-08-01 ES ES02016953T patent/ES2339426T3/es not_active Expired - Lifetime
- 2002-08-01 AT AT02016953T patent/ATE460483T1/de active
- 2002-08-01 SG SG200204673A patent/SG117416A1/en unknown
- 2002-08-01 DE DE10235248A patent/DE10235248B4/de not_active Expired - Fee Related
- 2002-08-01 EP EP02016953A patent/EP1319712B1/en not_active Expired - Lifetime
- 2002-08-02 FR FR0209867A patent/FR2832716B1/fr not_active Expired - Lifetime
- 2002-08-02 ZA ZA200206172A patent/ZA200206172B/xx unknown
- 2002-08-06 GB GB0218252A patent/GB2382580B/en not_active Expired - Fee Related
- 2002-08-08 IT IT001803A patent/ITMI20021803A1/it unknown
- 2002-08-20 BR BRPI0203394A patent/BRPI0203394B1/pt not_active IP Right Cessation
- 2002-08-21 MX MXPA02008131A patent/MXPA02008131A/es active IP Right Grant
- 2002-08-23 CN CNB021301557A patent/CN100390201C/zh not_active Expired - Fee Related
- 2002-08-29 US US10/230,454 patent/US7098318B2/en not_active Expired - Lifetime
- 2002-08-30 RU RU2002123438/15A patent/RU2225220C1/ru not_active IP Right Cessation
- 2002-08-30 JP JP2002253938A patent/JP3860097B2/ja not_active Expired - Fee Related
- 2002-08-30 AR ARP020103279A patent/AR036384A1/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2225220C1 (ru) | Слитый белок, обладающий in vivo повышенной активностью эритропоэтина | |
| EP1683864A3 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| AU5827800A (en) | Fabrication of beta-pleated sheet proteins with specific binding properties | |
| WO2002090553A3 (de) | Rekombinante fusionsproteine und deren trimere | |
| WO2001072976A3 (en) | 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor | |
| RU2002123286A (ru) | Слитый белок с увеличенной эритропоэтиновой активностью, нуклеиновая кислота, кодирующая слитый белок, и способ получения слитого белка | |
| WO1995004151A3 (en) | Vaccine compositions containing recombinant tetc-fusion proteins | |
| EP1688430A3 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| WO2002052029A9 (fr) | Methode permettant de produire une proteine de recombinaison et une proteine fusionnee | |
| AU5776799A (en) | Modified hcv peptide vaccines | |
| EP1270730A1 (en) | Process for producing polypeptide having disulfide bond | |
| WO2002070665A8 (en) | Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen | |
| CA2429138A1 (en) | Sol-fusin: use of gp64-6his to catalyze membrane fusion | |
| WO2002038769A3 (de) | Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen | |
| WO2001029224A3 (en) | Granulocyte peptide homolog zgpa1 | |
| WO2003012121A3 (en) | Collagen xxii, a novel human collagen and uses thereof | |
| WO2001064904A3 (en) | 25324, 50287, 28899, 47007, and 42967 transferase family members and uses therefor | |
| EP0845536A3 (en) | Protein having ethylenediamine-N,N'-disuccinic acid: ethylenediamine lyase activity and gene encoding the same | |
| WO2001070986A3 (en) | Helical protein zalpha51 | |
| EP1897944A3 (en) | IL-17 homologous polypeptides and therapeutic uses thereof | |
| WO2002029042A3 (en) | 48120, 23479, and 46689, novel human hydrolases and uses thereof | |
| JP2003527830A5 (ru) | ||
| AU2001251410A1 (en) | 12303, a novel human twik molecule and uses thereof | |
| WO2002006331A3 (en) | 14087, a serine protease molecule and uses therefor | |
| WO1999055876A3 (de) | Polypeptid mit immunogenen eigenschaften und veränderten biologischen funktionen eines proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Invention patent assignment |
Effective date: 20080911 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20150427 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180831 |